Literature DB >> 11780146

Structure of the Bcr-Abl oncoprotein oligomerization domain.

Xun Zhao1, Saghi Ghaffari, Harvey Lodish, Vladimir N Malashkevich, Peter S Kim.   

Abstract

The Bcr-Abl oncoprotein is responsible for a wide range of human leukemias, including most cases of Philadelphia chromosome-positive chronic myelogenous leukemia. Oligomerization of Bcr-Abl is essential for oncogenicity. We determined the crystal structure of the N-terminal oligomerization domain of Bcr-Abl (residues 1-72 or Bcr1-72) and found a novel mode of oligomer formation. Two N-shaped monomers dimerize by swapping N-terminal helices and by forming an antiparallel coiled coil between C-terminal helices. Two dimers then stack onto each other to form a tetramer. The Bcr1-72 structure provides a basis for the design of inhibitors of Bcr-Abl transforming activity by disrupting Bcr-Abl oligomerization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11780146     DOI: 10.1038/nsb747

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  49 in total

Review 1.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 2.  Targeting protein-protein interactions for cancer therapy.

Authors:  David C Fry; Lyubomir T Vassilev
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

3.  Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.

Authors:  Christina M Taylor; Amy E Keating
Journal:  Biochemistry       Date:  2005-12-13       Impact factor: 3.162

4.  The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase.

Authors:  Frank J Delfino; Jonathan M Shaffer; Thomas E Smithgall
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

5.  Disruption of Bcr-Abl coiled coil oligomerization by design.

Authors:  Andrew S Dixon; Scott S Pendley; Benjamin J Bruno; David W Woessner; Adrian A Shimpi; Thomas E Cheatham; Carol S Lim
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

6.  Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.

Authors:  Hai-Xia Wang; Heng Xiao; Liang Zhong; Kun Tao; Ya-Juan Li; Shi-Feng Huang; Jian-Ping Wen; Wen-Li Feng
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

7.  BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Chunggang Gao; Wengang Chen; Qin Huang; Jiing-Kuan Yee; Ravi Bhatia; WenYong Chen
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

Review 9.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

10.  Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.

Authors:  Hedi Hegyi; László Buday; Peter Tompa
Journal:  PLoS Comput Biol       Date:  2009-10-30       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.